Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 24.

Journal Article

Baertsch, Marc-A., Schlenzka, Jana, Christina, Habermehl, Hielscher, Thomas, Raab, Marc S., Hillengass, Jens, Mueller-Tidow, Carsten, Luntz, Steffen, Jauch, Anna, Brossart, Peter, Goerner, Martin, Klein, Stefan A., Schmidt-Hieber, Martin, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Haenel, Mathias, Martin, Hans, Lindemann, Hans-Walter, Scheid, Christoph, Nogai, Axel, Salwender, Hans Juergen, Noppeney, Richard, Weisel, Katja and Goldschmidt, Hartmut (2018). Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Baertsch, Marc-Andrea, Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Salwender, Hans J., Munder, Markus, Fuhrmann, Stephan ORCID: 0000-0002-7785-2565, Duehrsen, Ulrich, Brossart, Peter, Neben, Kai, Schlenzka, Jana, Kunz, Christina, Raab, Marc S., Hillengass, Jens, Jauch, Anna, Seckinger, Anja, Hose, Dirk, Luntz, Steffen, Sonneveld, Pieter, Lokhorst, Henk, Martin, Hans, Goerner, Martin, Hoffmann, Martin, Lindemann, Hans-Walter, Bernhard, Helga, Blau, Igor W., Scheid, Christof, Besemer, Britta, Weisel, Katja C., Haenel, Mathias, Duerig, Jan and Goldschmidt, Hartmut (2021). Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma. Blood Cancer J., 11 (1). LONDON: SPRINGERNATURE. ISSN 2044-5385

Baertsch, Marc-Andrea, Schlenzka, Jana, Mai, Elias K., Merz, Maximilian, Hillengass, Jens, Raab, Marc S., Hose, Dirk, Wuchter, Patrick, Ho, Anthony D. ORCID: 0000-0002-1656-0833, Jauch, Anna, Hielscher, Thomas, Kunz, Christina, Luntz, Steffen, Klein, Stefan, Schmidt-Wolf, Ingo G. H., Goerner, Martin, Schmidt-Hieber, Martin, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Salwender, Hans ORCID: 0000-0001-7803-0814, Scheid, Christof, Nogai, Axel, Haenel, Mathias, Lindemann, Hans W., Martin, Hans, Noppeney, Richard, Weisel, Katja and Goldschmidt, Hartmut (2016). Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma. BMC Cancer, 16. LONDON: BMC. ISSN 1471-2407

Dietrich, Sascha, Oles, Malgorzata, Lu, Junyan ORCID: 0000-0002-9211-0746, Sellner, Leopold ORCID: 0000-0002-7893-401X, Anders, Simon ORCID: 0000-0003-4868-1805, Velten, Britta, Wu, Bian, Huellein, Jennifer, Liberio, Michelle da Silva, Walther, Tatjana, Wagner, Lena, Rabe, Sophie, Ghidelli-Disse, Sonja, Bantscheff, Marcus, Oles, Andrzej K., Slabicki, Mikolaj, Mock, Andreas, Oakes, Christopher C., Wang, Shihui, Oppermann, Sina, Lukas, Marina, Kim, Vladislav, Sill, Martin ORCID: 0000-0001-7616-7665, Benner, Axel, Jauch, Anna, Sutton, Lesley Ann, Young, Emma, Rosenquist, Richard, Liu, Xiyang, Jethwa, Alexander ORCID: 0000-0003-3869-8662, Lee, Kwang Seok, Lewis, Joe, Putzker, Kerstin, Lutz, Christoph, Rossi, Davide, Mokhir, Andriy, Oellerich, Thomas, Zirlik, Katja, Herling, Marco, Nguyen-Khac, Florence ORCID: 0000-0003-3107-6668, Plass, Christoph, Andersson, Emma, Mustjoki, Satu ORCID: 0000-0002-0816-8241, von Kalle, Christof, Ho, Anthony D. ORCID: 0000-0002-1656-0833, Hensel, Manfred, Duerig, Jan, Ringshausen, Ingo ORCID: 0000-0002-7247-311X, Zapatka, Marc ORCID: 0000-0001-8287-5967, Huber, Wolfgang ORCID: 0000-0002-0474-2218 and Zenz, Thorsten (2018). Drug-perturbation-based stratification of blood cancer. J. Clin. Invest., 128 (1). S. 427 - 446. ANN ARBOR: AMER SOC CLINICAL INVESTIGATION INC. ISSN 1558-8238

Dikow, Nicola, Maas, Bianca, Gaspar, Harald, Kreiss-Nachtsheim, Martina, Engels, Hartmut, Kuechler, Alma, Garbes, Lutz, Netzer, Christian, Neuhann, Teresa M., Koehler, Udo, Casteels, Kristina, Devriendt, Koen, Janssen, Johannes W. G., Jauch, Anna, Hinderhofer, Katrin and Moog, Ute (2013). The Phenotypic Spectrum of Duplication 5q35.2-q35.3 Encompassing NSD1: Is It Really a Reversed Sotos Syndrome? Am. J. Med. Genet. A, 161 (9). S. 2158 - 2167. HOBOKEN: WILEY-BLACKWELL. ISSN 1552-4833

Goldschmidt, Hartmut, Baertsch, Marc-A., Schlenzka, Jana, Becker, Natalia, Christina, Habermehl, Hielscher, Thomas, Raab, Marc S., Hillengass, Jens, Mueller-Tidow, Carsten, Luntz, Steffen, Jauch, Anna, Brossart, Peter, Goerner, Martin, Klein, Stefan A., Schmidt-Hieber, Martin, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Haenel, Mathias, Martin, Hans, Lindemann, Hans-Walter, Scheid, Christoph, Nogai, Axel, Salwender, Hans Juergen, Noppeney, Richard and Weisel, Katja (2018). Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Goldschmidt, Hartmut, Baertsch, Marc-Andrea, Schlenzka, Jana, Becker, Natalia, Habermehl, Christina, Hielscher, Thomas, Raab, Marc-Steffen, Hillengass, Jens, Sauer, Sandra, Mueller-Tidow, Carsten, Luntz, Steffen, Jauch, Anna, Hose, Dirk, Seckinger, Anja, Brossart, Peter, Goerner, Martin, Klein, Stefan, Schmidt-Hieber, Martin, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Haenel, Mathias, Martin, Hans, Lindemann, Hans W., Scheid, Christoph, Nogai, Axel, Salwender, Hans, Noppeney, Richard, Besemer, Britta and Weisel, Katja . Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Goldschmidt, Hartmut, Mai, Elias K., Duerig, Jan, Scheid, Christof, Weisel, Katja C., Kunz, Christina, Bertsch, Uta, Hielscher, Thomas, Merz, Maximilian, Munder, Markus, Lindemann, Hans-Walter, Huegle-Doerr, Barbara, Tichy, Diana, Giesen, Nicola, Hose, Dirk, Seckinger, Anja, Huhn, Stefanie, Luntz, Steffen, Jauch, Anna, Elmaagacli, Ahmet, Rabold, Bernhard, Fuhrmann, Stephan, Brossart, Peter, Goerner, Martin, Bernhard, Helga, Hoffmann, Martin, Hillengass, Jens, Raab, Marc S., Blau, Igor W., Haenel, Mathias and Salwender, Hans J. (2020). Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia, 34 (7). S. 1853 - 1866. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Hose, Dirk, Beck, Susanne, Salwender, Hans, Emde, Martina, Bertsch, Uta, Kunz, Christina, Scheid, Christoph, Haenel, Mathias, Weisel, Katja, Hielscher, Thomas, Raab, Marc S., Goldschmidt, Hartmut, Jauch, Anna, Moreaux, Jerome ORCID: 0000-0002-5717-3207 and Seckinger, Anja (2019). Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial. J. Hematol. Oncol., 12. LONDON: BMC. ISSN 1756-8722

Klein, Eva-Maria, Tichy, Diana, Salwender, Hans J., Mai, Elias K., Duerig, Jan, Weisel, Katja C., Benner, Axel, Bertsch, Uta, Akhavanpoor, Mabast, Besemer, Britta, Munder, Markus, Lindemann, Hans-Walter, Hose, Dirk, Seckinger, Anja, Luntz, Steffen, Jauch, Anna, Elmaagacli, Ahmet, Fuhrmann, Stephan, Brossart, Peter, Goerner, Martin, Bernhard, Helga, Raab, Marc S., Blau, Igor W., Haenel, Mathias, Scheid, Christof and Goldschmidt, Hartmut (2021). Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial. Cancers, 13 (19). BASEL: MDPI. ISSN 2072-6694

Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Schlenzka, Jana, Salwender, Hans J., Munder, Markus, Gerecke, Christian, Duehrsen, Ulrich, Brossart, Peter, Neben, Kai, Hillengass, Jens, Raab, Marc S., Merz, Maximilian, Baertsch, Marc-Andrea, Jauch, Anna, Hose, Dirk, Martin, Hans, Lindemann, Hans-Walter, Blau, Igor W., Scheid, Christof, Weisel, Katja C. and Goldschmidt, Hartmut (2019). Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma. Leukemia, 33 (1). S. 258 - 262. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Mai, Elias K., Huhn, Stefanie, Miah, Kaya, Poos, Alexandra M., Scheid, Christof, Weisel, Katja, Bertsch, Uta, Munder, Markus, Berlanga, Oscar, Hose, Dirk, Seckinger, Anja, Jauch, Anna, Blau, Igor Wolfgang, Haenel, Mathias, Salwender, Hans, Benner, Axel, Raab, Marc S., Goldschmidt, Hartmut and Weinhold, Niels (2022). Implications and Prognostic Impact of Mass Spectrometry in Patients with Newly-Diagnosed Multiple Myeloma. Blood, 140. S. 2341 - 2344. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Mai, Elias K., Miah, Kaya, Bertsch, Uta, Duerig, Jan, Scheid, Christof, Weisel, Katja C., Kunz, Christina, Munder, Markus, Lindemann, Hans-Walter, Merz, Maximilian, Hose, Dirk, Jauch, Anna, Seckinger, Anja, Luntz, Steffen, Sauer, Sandra, Fuhrmann, Stephan, Brossart, Peter, Elmaagacli, Ahmet, Goerner, Martin, Bernhard, Helga, Hoffmann, Martin, Raab, Marc S., Blau, Igor W., Haenel, Mathias, Benner, Axel, Salwender, Hans J. and Goldschmidt, Hartmut . Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age. Leukemia. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Merz, Maximilian, Jauch, Anna, Hielscher, Thomas, Bochtler, Tilmann, Schoenland, Stefan Olaf, Seckinger, Anja, Hose, Dirk, Bertsch, Uta, Neben, Kai, Raab, Marc Steffen, Hillengass, Jens, Salwender, Hans, Blau, Igor Wolfgang, Lindemann, Hans-Walter, Schmidt-Wolf, Ingo G. H., Scheid, Christof, Haenel, Mathias, Weisel, Katja C. and Goldschmidt, Hartmut (2018). Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma. Blood Adv., 2 (1). S. 1 - 10. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 2473-9537

Merz, Maximilian, Jauch, Anna, Hielscher, Thomas, Mai, Elias K., Seckinger, Anja, Hose, Dirk, Bertsch, Uta, Neben, Kai, Raab, Marc S., Salwender, Hans ORCID: 0000-0001-7803-0814, Blau, Igor W., Lindemann, Hans-Walter, Schmidt-Wolf, Ingo, Scheid, Christof, Haenel, Mathias, Weisel, Katja, Goldschmidt, Hartmut and Hillengass, Jens (2017). Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation. Haematologica, 102 (8). S. 1432 - 1439. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Merz, Maximilian, Salwender, Hans ORCID: 0000-0001-7803-0814, Haenel, Mathias, Mai, Elias K., Bertsch, Uta, Kunz, Christina, Hielscher, Thomas, Blau, Igor W., Scheid, Christof, Hose, Dirk, Seckinger, Anja, Jauch, Anna, Hillengass, Jens, Raab, Marc S., Schurich, Baerbel, Munder, Markus, Brossart, Peter, Gerecke, Christian, Lindemann, Hans-Walter, Zeis, Matthias, Weisel, Katja, Duerig, Jan and Goldschmidt, Hartmut (2016). Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. Haematologica, 101 (12). S. E485 - 3. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Salwender, Hans, Bertsch, Uta, Weisel, Katja, Duerig, Jan, Kunz, Christina, Benner, Axel, Blau, Igor W., Raab, Marc Steffen, Hillengass, Jens, Hose, Dirk, Huhn, Stefanie, Hundemer, Michael, Andrulis, Mindaugas, Jauch, Anna, Seidel-Glaetzer, Andrea, Lindemann, Hans-Walter, Hensel, Manfred, Fronhoffs, Stefan, Martens, Uwe, Hansen, Timon, Wattad, Mohammed, Graeven, Ullrich, Munder, Markus, Fenk, Roland, Haenel, Mathias, Scheid, Christof and Goldschmidt, Hartmut (2019). Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. BMC Cancer, 19. LONDON: BMC. ISSN 1471-2407

Salwender, Hans, Elmaagacli, Ahmet, Merz, Maximilian, Miah, Kaya, Benner, Axel, Haenel, Mathias, Jehn, Christian, Mai, Elias K., Bertsch, Uta, Blau, Igor W., Scheid, Christof, Hose, Dirk, Seckinger, Anja, Jauch, Anna, Raab, Marc S., Luntz, Steffen P., Besemer, Britta, Munder, Markus, Brossart, Peter, Fuhrmann, Stephan, Lindemann, Hans-Walter, Weisel, Katja, Duerig, Jan and Goldschmidt, Hartmut (2021). Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial. Leukemia, 35 (10). S. 3007 - 3012. LONDON: SPRINGERNATURE. ISSN 1476-5551

Scheid, Christof, Hielscher, Thomas, Bertsch, Uta, Kunz, Christina, Salwender, Hans, Haenel, Mathias, Merz, Maximilian, Mai, Elias Karl ORCID: 0000-0002-6226-1252, Hose, Dirk, Schurich, Baerbel, Munder, Markus, Schmidt-Wolf, Ingo, Gerecke, Christian, Lindemann, Walter, Zeis, Matthias, Weisel, Katja, Duerig, Jan, Jauch, Anna and Goldschmidt, Hartmut (2014). Influence of Renal Impairment and Genetic Risk Factors on Response to Induction Therapy in the HD4 and MM5 Trials of the GMMG. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Seckinger, Anja, Salwender, Hans Juergen, Martin, Hans, Scheid, Christof, Hielscher, Thomas, Bertsch, Uta, Hummel, Manuela, Jauch, Anna, Knauf, Wolfgang, Emde, Martina, Beck, Susanne, Neben, Kai, Lokhorst, Henk M., van der Holt, Bronno, Duehrsen, Ulrich, Duerig, Jan, Lindemann, Hans-Walter, Schmidt-Wolf, Ingo, Haenel, Mathias, Lathan, Bernd, Raab, Marc S., Mueller-Tidow, Carsten, Sonneveld, Pieter, Blau, Igor Wolfgang, Hillengass, Jens, Weisel, Katja, Goldschmidt, Hartmut and Hose, Dirk (2018). Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trail - Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Sellner, Leopold, Oles, Malgorzata, Slabicki, Mikolaj, Blume, Carolin, Huellein, Jennifer, Stolz, Tatjana, Lukas, Marina, Sill, Martin, Oakes, Christopher C., Dietrich, Sascha, Merkel, Olaf, Jauch, Anna, Hensel, Manfred, Rossi, Davide, Zirlik, Katja, Duerig, Jan, Ringshausen, Ingo, Herling, Marco, Seiffert, Martina ORCID: 0000-0001-5155-663X, Dreger, Peter, von Kalle, Christof, Ho, Anthony D., Glimm, Hanno, Huber, Wolfgang and Zenz, Thorsten (2014). Systematic mapping of drug sensitivity in hematological malignancies identifies vulnerability of chronic lymphocytic leukemia with mutant p53. Cancer Res., 74 (19). PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Sonneveld, Pieter, Salwender, Hans-Juergen, Van der Holt, Bronno, el Jarari, Laila, Bertsch, Uta, Blau, Igor W., Zweegman, Sonja, Weisel, Katja C., Vellenga, Edo, Pfreundschuh, Michael, Broijl, Annemiek, Scheid, Christof, Wittebol, Shulamiet, Bos, Gerard M. J., Stevens-Kroef, Marjan, Jauch, Anna, Potamianou, Anna, Hose, Dirk, Raymakers, Reinier, Schaafsme, Marinus, Kersten, Marie Jose, Kooy, Marinus van Marwijk, Duehrsen, Ulrich, Lindemann, Hans Walter, Brossart, Peter, Wijermans, Pierre, Lokhorst, Henk M. and Goldschmidt, Hartmut (2015). Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Weinhold, Niels, Salwender, Hans J., Cairns, David A., Raab, Marc S., Waldron, George, Blau, Igor W., Bertsch, Uta, Hielscher, Thomas, Morgan, Gareth J., Jauch, Anna, Davies, Faith E., Hanel, Mathias, Cook, Gordon ORCID: 0000-0003-1717-0412, Scheid, Christoph, Houlston, Richard ORCID: 0000-0002-5268-0242, Goldschmidt, Hartmut, Jackson, Graham and Kaiser, Martin F. (2021). Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients. Haematologica, 106 (10). S. 2754 - 2759. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Weisel, Katja, Besemer, Britta, Haenel, Mathias, Lutz, Raphael, Mann, Christoph, Munder, Markus, Goerner, Martin, Reinhardt, Hans Christian, Nogai, Axel, Ko, Yon-Dschun, De Wit, Maike, Salwender, Hans, Scheid, Christoph, Graeven, Ullrich, Peceny, Rudolf, Staib, Peter, Dieing, Annette, Jauch, Anna, Zago, Manola, Benner, Axel, Tichy, Diana, Bokemeyer, Carsten, Goldschmidt, Hartmut and Leypoldt, Lisa B. (2022). Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial. Blood, 140. S. 1836 - 1839. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

This list was generated on Fri Apr 19 16:24:21 2024 CEST.